Cargando…
Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680670/ https://www.ncbi.nlm.nih.gov/pubmed/33225405 http://dx.doi.org/10.1007/s13760-020-01551-8 |
| _version_ | 1783612479664816128 |
|---|---|
| author | Finsterer, J. |
| author_facet | Finsterer, J. |
| author_sort | Finsterer, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7680670 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76806702020-11-23 Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy Finsterer, J. Acta Neurol Belg Letter to the Editor Springer International Publishing 2020-11-23 2021 /pmc/articles/PMC7680670/ /pubmed/33225405 http://dx.doi.org/10.1007/s13760-020-01551-8 Text en © Belgian Neurological Society 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Finsterer, J. Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title | Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title_full | Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title_fullStr | Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title_full_unstemmed | Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title_short | Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy |
| title_sort | myotoxic drugs and immunodeficiency may contribute to the poor outcome of covid-19 patients with myotonic dystrophy |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680670/ https://www.ncbi.nlm.nih.gov/pubmed/33225405 http://dx.doi.org/10.1007/s13760-020-01551-8 |
| work_keys_str_mv | AT finstererj myotoxicdrugsandimmunodeficiencymaycontributetothepooroutcomeofcovid19patientswithmyotonicdystrophy |